€255.68
€255.68
Tirz is an antidiabetic peptide used to treat type 2 diabetes and to promote weight loss. It is administered by subcutaneous injection. Tirz acts on two types of receptors: GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide). Both of these hormones are involved in blood sugar control and are secreted by intestinal cells after food consumption, leading to insulin secretion. Tirz as a long-acting GIP analog activates both of these receptors, leading to improved glycemic control【14†source】.
It increases tissue sensitivity to insulin and enhances its secretion by pancreatic beta cells, which contributes to lowering blood glucose levels during fasting and after meals. Tirz also delays gastric emptying, which reduces glucose absorption from meals, reduces appetite and increases satiety, leading to weight and fat reduction【12†source】.
Tirz differs from semaglutide, another drug for type 2 diabetes and obesity, in that it also mimics the GIP hormone, which affects not only the delay of gastric emptying and appetite, but also the way fat is deposited in the body【13†source】.
It was approved by the FDA (U.S. Food and Drug Administration) for the treatment of type 2 diabetes in May 2022. Studies have shown that tirz can help people lose an average of 27% of their body weight in a year and a half when used in conjunction with diet and exercise【13†source】. Tirz is indicated to improve blood sugar control in adults with type 2 diabetes as an adjunct to diet and exercise, and to support weight management with a calorie-restricted diet and increased physical activity【14†source】.
The substance is not a food product or dietary supplement, it is not suitable for human consumption. The product is classified as a chemical reagent approved for marketing in the European Union, and can only be used for scientific research.
| 5 star | 0% | |
| 4 star | 0% | |
| 3 star | 0% | |
| 2 star | 0% | |
| 1 star | 0% |
Sorry, no reviews match your current selections
Reta (LY-3437943) is an investigational peptide for the treatment of obesity and type 2 diabetes. It acts as a triple receptor agonist, targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and glucagon. This complex approach is designed to manage blood sugar levels and aid weight loss more effectively than drugs that act on a single receptor.
€124.48
CARGI is an investigational, novel, long-acting acylated amylin analog that acts as a non-selective agonist of amylin receptors (AMYR) and calcitonin G-protein-coupled receptors (CTR). Cargi induces significant weight loss and reduces food intake.
€178.88
Cagri acts as an innovative long-acting amylin analog that activates both amylin and calcitonin receptors. Its uniqueness lies in its ability to trigger a satiety signal in the brain, affecting areas of the brain responsible for both homeostasis and enjoyment of food. Through this mechanism, cagri has the potential to reduce food intake and promote weight loss for patients. In addition, its long-lasting effect allows application once a week, which is convenient for patients
€223.68
Sema is a drug designed to mimic the hormone glucagon-like peptide-1 (GLP-1), which occurs naturally in the body. GLP-1 is produced in the gastrointestinal tract in response to the food consumed.
Original price was: €478.40.€351.68Current price is: €351.68.
We take pride in treating every customer, big or small, with the utmost respect.
Receive a 10% discount on your first purchases.
© 2024 Peptideeurope.eu All Rights Reserved.
All products on this site are for research and development purposes only. The products are not intended for human consumption.
The statements made on this page have not been evaluated by the US Food and Drug Administration. Food and Drug Administration. The statements and products of this company are not intended to diagnose, treat or prevent any disease.
